Candidiasis or commonly known as thrush is a fungal infection affecting men and women of all age groups. When thrush extends into the throat it causes esophagitis. It is also known by other names such as candidosis, moniliasis, and oidiomycosis. The effects of this infection are seen on a dermal, internal and systemic level wherein it is known as candidemia or intestinal thrush. The market is dynamic due to widespread occurrence of this disease, in particular as recurrent infections, limitations of safe and efficacious antifungals as well as the lack of reliable preventative approaches. The major drug classes for treatment include azoles, polyenes and echinocandins.
Candidiasis Therapeutics Market: Drivers and Restraints
Increase in number of patients affected by candidiasis infection, increasing consumer inclination towards maintaining aesthetic appearance and growing awareness for candidiasis infection in developing markets are expected to boost the market growth over the forecast period. This is mainly due to urbanization and rising hygiene awareness in developing countries. Less R&D activity in this sector and availability of alternative treatments is expected to restraint the candidiasis therapeutics market over the forecast year. The factors such as narrow pipeline molecules and competition from herbal medicines and alternate therapies such as probiotic are expected to restrain the market growth over the forecast period.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1327
Candidiasis Therapeutics Market: Segmentation
Candidiasismarket is classified on the basis of route of administration, drug type, anatomy type and distribution channel:
Based on route of administration, the global candidiasis therapeutics marketcan be segmented as follows:
Based on class of drugs, the global candidiasis therapeutics marketcan be segmented as follows:
Based on anatomy type, the global candidiasis therapeutics marketcan be segmented as follows:
- Oral Candidiasis
- Vulvovaginal Candidiasis
- Cutaneous Candidiasis
- Invasive Candidiasis
- Systemic Candidiasis
Based on distribution channel, the global candidiasis therapeutics market can be segmented as follows:
- Retail Pharmacies
- Drug Stores
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1327
Candidiasis Therapeutics Market: Overview
The global market for anti-candidiasis agents is expected to grow with a healthy CAGR over the forecast period. The market for systemic candidiasis is driven by increases in the susceptible immune compromised patient pool. Thrush occurs in approximately 2–5 percent of healthy new born and affect them mainly during their first year of life. Over 1 million adult women and adolescent girls in the U. S. develop vaginal yeast infections each year.
Candidiasis Therapeutics Market: Region-wise Outlook
Based on geographic regions, gastroesophageal reflux disease therapeutics market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific and Middle East & Africa. The disease is growing globally and is not restricted to any particular region. North America and Europe region account for the largest markets revenue share due to higher awareness of the disease amongst individuals and also availability of better treatment. Asia-Pacific also offers considerable opportunities owing to low unmet need in this region.
Browse Full Report@ http://www.futuremarketinsights.com/reports/candidiasis-therapeutics-market
Candidiasis Therapeutics Market: Key Players
The anti-fungal candidiasis treatment is a highly fragmented mature market with a large number of generics. Major players in the market are Bayer, Teva Pharmaceuticals, Stellar Pharma, Pfizer, Wockhardt, Ranbaxy, Bristol Laboratories, Glenmark Pharmaceuticals, Taro Pharmaceuticals and Perrigo among many other local players. There are several types of formulations available for treatment based on the modality such as pills, powders, ointments and injectable. In 2013, Astellas Pharma reported positive results from its phase III drug isavuconazole which is one of the only first-in-class molecules expected to enter the market.